公开(公告)号：WO2017021535A1

公开(公告)日：2017-02-09

申请号：PCT/EP2016/068767

申请日：2016-08-05

Applicant: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD ,  UNIVERSIDAD PABLO DE OLAVIDE ,  NEW BIOTECHNIC, S.A.

Inventor： SORIA ESCOMS, Bernat ,  HMADCHA, Abdelkrim ,  TEJEDO HUAMAN, Juan Rigoberto ,  BEDOYA BERGUA, Francisco, Javier

IPC: C12N5/00

CPC classification number: C12N5/0667 ,  C12N5/0663 ,  C12N2501/03

Abstract: The invention provides new culture media and methods for hPCs' isolation and expansion using said media, which provide significant advantages over known culture media and isolation and expansion methods. These culture media are characterized by the presence of a nitric oxide donor. In addition the culture media of the invention are preferably serum supplemented or serum-free.

Abstract translation: 本发明提供使用所述培养基的hPCs分离和扩增的新的培养基和方法，其提供了超过已知培养基和分离和扩增方法的显着优点。 这些培养基的特征在于存在一氧化氮供体。 此外，本发明的培养基优选为补充血清或​​不含血清。

公开(公告)号：WO2008034929A1

公开(公告)日：2008-03-27

申请号：PCT/ES2007/000537

申请日：2007-09-18

Applicant: FUNDACIÓN PROGRESO Y SALUD ,  UNIVERSIDAD PABLO DE OLAVIDE ,  SORIA ESCOMS, Bernat ,  TEJEDO HUAMAN, Juan Rigoberto ,  BEDOYA BERGUA, Francisco Javier

Inventor： SORIA ESCOMS, Bernat ,  TEJEDO HUAMAN, Juan Rigoberto ,  BEDOYA BERGUA, Francisco Javier

IPC: C12N5/06 ,  C12N5/08 ,  C12N5/16 ,  C12N5/22

CPC classification number: C12N5/0606 ,  C12N2500/44 ,  C12N2501/03

Abstract: El mantenimiento en cultivo de las células pluripotenciales y progenitoras en estado no diferenciado presenta diversos problemas dependiendo del tipo, origen y uso futuro de las células. Actualmente es posible realizar el cultivo de las células pluripotenciales de mamífero en sistemas que mantengan su estado no diferenciado; sin embargo la diferenciación espontánea inherente al cultivo es alta, situación que genera dificultades en los procedimientos para obtener células. El procedimiento objeto de la presente invención permite el mantenimiento y cultivo de células pluripotenciales y progenitoras de mamífero en estado no diferenciado mediante la utilización de óxido nítrico.

Abstract translation:

文化维护C＆eacute的;多能祖细胞和未分化的状态呈现取决于类型，来源和C＆eacute的将来使用不同的问题;细胞。 现在有可能在维持其未分化状态的系统中培养多能哺乳动物细胞; 然而，文化固有的自发分化很高，这种情况在获得细胞的过程中产生困难。 本invenci＆冲突和的方法允许维持和培养的C＆eacute;干细胞和祖MAM RIVER我FERO在未分化的状态下，通过利用＆oacute; N＆COLLISION我xidoÑRIVER点火器。

公开(公告)号：WO01021220A3

公开(公告)日：2001-10-25

申请号：PCT/US2000/025991

申请日：2000-09-21

IPC: A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/7052 ,  A61K35/12 ,  A61K48/00 ,  A61L27/36 ,  A61L27/38 ,  C12N5/071 ,  G01N33/50 ,  A61F2/24

CPC classification number: G01N33/5011 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/5377 ,  A61K31/7052 ,  A61K38/44 ,  A61K48/005 ,  A61K48/0075 ,  A61L27/3625 ,  A61L27/3645 ,  A61L27/3683 ,  A61L27/3695 ,  A61L27/38 ,  A61L27/507 ,  C12N5/0602 ,  C12N15/86 ,  C12N2501/03 ,  C12N2501/70 ,  C12N2510/00 ,  C12N2710/10343 ,  C12Y114/13039 ,  G01N33/5008 ,  G01N33/5061 ,  G01N33/5064 ,  G01N33/5088 ,  A61K2300/00

Abstract: The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

Abstract translation: 本发明提供了与心脏瓣膜相关的方法和材料以及瓣膜性心脏病的治疗。 具体而言，本发明提供非鼠类心脏瓣膜细胞和心脏瓣膜尖端以及制造心脏瓣膜的方法。 本发明还提供了（1）减慢心脏瓣膜变性，血栓形成和钙化的方法和材料，（2）治疗类癌心脏病，（3）鉴别心脏瓣膜变性，血栓形成和钙化的抑制剂，以及（4）确定 药物安全

公开(公告)号：WO2009155041A3

公开(公告)日：2010-03-11

申请号：PCT/US2009045442

申请日：2009-05-28

Applicant: CHILDRENS MEDICAL CENTER ,  GEN HOSPITAL CORP ,  BETH ISRAEL HOSPITAL ,  BRIGHAM & WOMENS HOSPITAL ,  ZON LEONARD I ,  NORTH TRISTA E ,  GOESSLING WOLFRAM

Inventor： ZON LEONARD I ,  NORTH TRISTA E ,  GOESSLING WOLFRAM

IPC: C12N5/02 ,  A61K31/04 ,  A61P37/06 ,  C12N5/00

CPC classification number: A61K31/00 ,  A61K31/04 ,  C12N5/0647 ,  C12N2501/03 ,  C12N2506/02 ,  C12N2506/11 ,  C12N2506/45

Abstract: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.

Abstract translation: 本文描述了与操纵造血干细胞（HSC）相关的方法，组合物和试剂盒，更具体地涉及与体外，离体和/或体内增加造血干细胞数量有关的方法，组合物和试剂盒。 还描述了与制造HSC的扩大群体相关的方法，组合物和试剂盒以及与使用HSC的扩展群体相关的方法，组合物和试剂盒。 例如，可通过使新生干细胞或HSC与刺激一氧化氮信号通路的药物接触来增强HSC生长。

公开(公告)号：WO2006081619A1

公开(公告)日：2006-08-10

申请号：PCT/AU2006/000132

申请日：2006-02-02

Applicant: NEWSOUTH INNOVATIONS PTY LIMITED ,  HALL, Bruce, Milne ,  HODGKINSON, Suzanne, Jean

Inventor： HALL, Bruce, Milne ,  HODGKINSON, Suzanne, Jean

IPC: C12N5/08

CPC classification number: C12N5/0636 ,  A61K2035/122 ,  C12N2501/03 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2501/25

Abstract: The invention relates to a method of growing CD4+,CD25+ T cells in vitro, comprising culturing CD4+,CD25+ T cells under conditions that inhibit the effect of nitric oxide production on the survival and/or proliferation of CD4+,CD25+ T cells. The invention also relates to methods of increasing tolerance in a subject by administering CD4+, CD25+ T cells grown in vitro.

Abstract translation: 本发明涉及体外培养CD4 +，CD25 + T细胞的方法，包括在抑制一氧化氮产生对CD4 +，CD25 + T细胞的存活和/或增殖的作用的条件下培养CD4 +，CD25 + T细胞。 本发明还涉及通过施用体外生长的CD4 +，CD25 + T细胞增加受试者耐受性的方法。

公开(公告)号：WO0057861A3

公开(公告)日：2001-03-08

申请号：PCT/CA0000334

申请日：2000-03-28

Applicant: IAF BIOCHEM INT ,  GOURDEAU HENRIETTE ,  GILES FRANCIS J

Inventor： GOURDEAU HENRIETTE ,  GILES FRANCIS J

IPC: C07D405/04 ,  A61K20060101 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/675 ,  A61K31/70 ,  A61K31/704 ,  A61K31/7068 ,  A61K35/12 ,  A61K35/14 ,  A61K38/00 ,  A61K38/06 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/22 ,  A61K39/395 ,  A61K45/06 ,  A61P35/02 ,  C12N5/078

CPC classification number: A61K31/675 ,  A61K31/506 ,  A61K31/70 ,  A61K31/704 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/212 ,  A61K38/32 ,  A61K39/39541 ,  A61K45/06 ,  A61K2035/124 ,  C12N5/0644 ,  C12N2501/03 ,  C12N2501/145 ,  A61K31/505 ,  A61K38/19 ,  A61K2300/00 ,  A61K38/20

Abstract: The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having formula (I): wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and (a) wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (-) enantiomer.

Abstract translation: 本发明提供一种用于治疗宿主中白血病，特别是急性骨髓性白血病（AML）的新方法，其包括向宿主施用治疗有效量的具有式（I）的化合物：其中B为胞嘧啶或5-氟胞嘧啶，R 选自H，单磷酸，二磷酸，三磷酸，被C 1-6烷基取代的羰基，C 2-6烯基，C 2-6炔基，C 6-10芳基和（a）其中每个R c独立地选自 基团，其包含H，C 1-6烷基，C 2-6烯基，C 2-6炔基和羟基保护基; 并且其中所述化合物基本上为（ - ）对映异构体的形式。

公开(公告)号：WO0121220A9

公开(公告)日：2002-11-07

申请号：PCT/US0025991

申请日：2000-09-21

Applicant: MAYO FOUNDATION ,  RAJAMANNAN NALINI M

Inventor： RAJAMANNAN NALINI M

IPC: A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/7052 ,  A61K35/12 ,  A61K48/00 ,  A61L27/36 ,  A61L27/38 ,  C12N5/071 ,  G01N33/50 ,  A61F2/24

CPC classification number: G01N33/5011 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/5377 ,  A61K31/7052 ,  A61K38/44 ,  A61K48/005 ,  A61K48/0075 ,  A61L27/3625 ,  A61L27/3645 ,  A61L27/3683 ,  A61L27/3695 ,  A61L27/38 ,  A61L27/507 ,  C12N5/0602 ,  C12N15/86 ,  C12N2501/03 ,  C12N2501/70 ,  C12N2510/00 ,  C12N2710/10343 ,  C12Y114/13039 ,  G01N33/5008 ,  G01N33/5061 ,  G01N33/5064 ,  G01N33/5088 ,  A61K2300/00

Abstract: The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

Abstract translation: 本发明提供了与心脏瓣膜相关的方法和材料以及瓣膜性心脏病的治疗。 具体而言，本发明提供非鼠类心脏瓣膜细胞和心脏瓣膜尖端以及制造心脏瓣膜的方法。 本发明还提供了（1）减慢心脏瓣膜变性，血栓形成和钙化的方法和材料，（2）治疗类癌心脏病，（3）鉴别心脏瓣膜变性，血栓形成和钙化的抑制剂，以及（4）确定 药物安全

公开(公告)号：WO00057891A1

公开(公告)日：2000-10-05

申请号：PCT/US2000/006436

申请日：2000-03-30

IPC: A61K35/12 ,  A61K35/14 ,  A61K35/19 ,  A61K38/06 ,  A61K38/19 ,  A61K45/06 ,  C12N5/078 ,  A61K33/00

CPC classification number: C12N5/0644 ,  A61K31/198 ,  A61K31/401 ,  A61K31/573 ,  A61K35/19 ,  A61K38/06 ,  A61K38/196 ,  A61K45/06 ,  C12N2501/03 ,  C12N2501/145 ,  A61K2300/00

Abstract: The present invention describes novel compositions and methods to enhance the in vitro and in vivo production of platelets and/or proplatelets from megakaryocytes. The present invention describes compositions comprising megakaryocytes, nitric oxide donors (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase), and, optionally, at least one thrombopoiesis stimulating factor. The thrombopoiesis stimulating factor is preferably thrombopoietin. The nitric oxide donor is preferable S-nitrosoglutathione. The present invention also describes compositions comprising at least one nitric oxide donor and at least one thrombopoiesis stimulating factor. The present invention also provides methods for treating and/or preventing blood platelet disorders, and for producing platelets and/or proplatelets in vitro and in vivo. The compounds and/or compositions of the present invention can be provided in the form of a pharmaceutical kit.

Abstract translation: 本发明描述了增强来自巨核细胞的血小板和/或血小板的体外和体内产生的新型组合物和方法。 本发明描述了包含巨核细胞，一氧化氮供体（即捐赠，转移或释放一氧化氮的化合物，提高内源性内源性舒张因子水平，刺激一氧化氮的内源性合成或一氧化氮合酶的底物）的组合物， 任选地，至少一种血小板生成刺激因子。 血小板生成刺激因子优选为血小板生成素。 一氧化氮供体优选S-亚硝基谷胱甘肽。 本发明还描述了包含至少一种一氧化氮供体和至少一种血小板生成刺激因子的组合物。 本发明还提供了用于治疗和/或预防血小板疾病以及用于在体外和体内产生血小板和/或血小板的方法。 本发明的化合物和/或组合物可以以药物试剂盒的形式提供。

公开(公告)号：WO00057861A2

公开(公告)日：2000-10-05

申请号：PCT/CA2000/000334

申请日：2000-03-28

IPC: C07D405/04 ,  A61K20060101 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/675 ,  A61K31/70 ,  A61K31/704 ,  A61K31/7068 ,  A61K35/12 ,  A61K35/14 ,  A61K38/00 ,  A61K38/06 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/22 ,  A61K39/395 ,  A61K45/06 ,  A61P35/02 ,  C12N5/078

CPC classification number: A61K31/675 ,  A61K31/506 ,  A61K31/70 ,  A61K31/704 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/212 ,  A61K38/32 ,  A61K39/39541 ,  A61K45/06 ,  A61K2035/124 ,  C12N5/0644 ,  C12N2501/03 ,  C12N2501/145 ,  A61K31/505 ,  A61K38/19 ,  A61K2300/00 ,  A61K38/20

Abstract: The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having formula (I): wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and (a) wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (-) enantiomer.

Abstract translation: 本发明提供一种用于治疗宿主中白血病，特别是急性骨髓性白血病（AML）的新方法，其包括向宿主施用治疗有效量的具有式（I）的化合物：其中B为胞嘧啶或5-氟胞嘧啶，R 选自H，单磷酸，二磷酸，三磷酸，被C 1-6烷基取代的羰基，C 2-6烯基，C 2-6炔基，C 6-10芳基和（a）其中每个R c独立地选自 基团，其包含H，C 1-6烷基，C 2-6烯基，C 2-6炔基和羟基保护基; 并且其中所述化合物基本上为（ - ）对映异构体的形式。

公开(公告)号：WO2016038038A1

公开(公告)日：2016-03-17

申请号：PCT/EP2015/070501

申请日：2015-09-08

Applicant: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD ,  UNIVERSIDAD PABLO DE OLAVIDE OTRI ,  INSTITUTO DE SALUD CARLOS III ,  NEWBIOTECHNIC S.A.

Inventor： SORIA ESCOMS, Bernat ,  SALGUERO-ARANDA, Carmen ,  HMADCHA, Abdelkrim ,  BEDOYA BERGUA, Francisco Javier ,  TEJERO HUAMÁN, Juan Rigoberto ,  MARTÍN BERMUDO, Francisco M. ,  TAPIA LIMONCHI, Rafael

IPC: C12N5/0735 ,  C12N5/071

CPC classification number: C12N5/0676 ,  C12N2501/03 ,  C12N2501/065 ,  C12N2501/999 ,  C12N2506/02

Abstract: Insulin producing cells capable of secreting blood glucose regulating hormones, specially insulin, in response to physiological signals, method of production of said cells and uses thereof.

Abstract translation: 能够分泌血糖调节激素的胰岛素生成细胞，特别是胰岛素，响应于生理信号，所述细胞的产生方法及其用途。